Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

uniQure (NASDAQ:QURE – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday .The stock traded as high as $18.18 and last traded at $18.18, with a volume of 29630 ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

uniQure (NASDAQ:QURE – Get Free Report)’s share price gapped up prior to trading on Tuesday .The stock had previously closed at $17.43, but opened at $17.88. uniQure shares last traded at $16. ...

FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ As part of uniQure’s ...

Stifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is “compelled” by the already developing efficacy ...

Raymond James analyst Danielle Brill upgraded uniQure (QURE) to Strong Buy from Outperform with a price target of $52, up from $20. Discover top-rated stocks from highly ranked analysts with ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Bullish option flow detected in uniQure (QURE) with 6,527 calls trading, 2x expected, and implied vol increasing over 14 points to 82.58%. Jan-25 17 calls and Jan-25 22 calls are the most active ...

Wells Fargo analyst Yanan Zhu upgraded uniQure (QURE) to Overweight from Equal Weight with a price target of $35, up from $14. With FDA alignment reached on the accelerated approval pathway for ...

uniQure (QURE) N.V. announced that the company reached agreement with the U.S. Food and Drug Administration, FDA, on key elements of an Accelerated Approval pathway for AMT-130. As part of uniQure ...